Centogene N.V. (CNTGF)
OTCMKTS · Delayed Price · Currency is USD
0.0630
+0.0070 (12.50%)
Aug 1, 2025, 4:00 PM EDT
Acelyrin Revenue
In the year 2023, Centogene had annual revenue of 48.54M EUR with 2.24% growth. Centogene had revenue of 23.91M in the half year ending December 31, 2023, a decrease of -221.89%.
Revenue
48.54M EUR
Revenue Growth
+2.24%
P/S Ratio
0.04
Revenue / Employee
126.40K EUR
Employees
384
Market Cap
1.89M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 48.54M | 1.06M | 2.24% |
Dec 31, 2022 | 47.47M | 5.24M | 12.40% |
Dec 31, 2021 | 42.23M | 3.78M | 9.83% |
Jan 1, 2021 | 38.45M | -10.33M | -21.17% |
Dec 31, 2019 | 48.78M | 8.30M | 20.51% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
American Oncology Network | 1.76B |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |